Jiangxi Rimag Group Co., Ltd. Class H (HK:2522)
:2522
Want to see HK:2522 full AI Analyst Report?
Top Page
Jiangxi Rimag Group Co., Ltd. Class H
(2522)
Select Model
Select Model
Rating:54Neutral
Price Target:
HK$6.50
▼(-19.75% Downside)
Action:Reiterated
Date:04/21/26
The score is driven primarily by recovering (but still volatile) financial performance, including a return to profit and much stronger operating cash flow in 2025. Technicals add moderate support via positive near-term momentum, but the longer-term trend remains weak and indicators look stretched. Valuation is the biggest drag due to an extremely high P/E.
Positive Factors
Return to revenue growth and net profit
A reversion to revenue growth and a return to positive net income indicate the core care-facilities operations regained traction. Sustained top-line recovery and even modest profits increase capacity to fund operations, rebuild margins and support multi‑period planning.
Negative Factors
Highly volatile free cash flow
Large swings in free cash flow point to material variability in capex or working capital needs and weaken predictability of cash available for dividends, debt reduction or reinvestment. Persistent FCF volatility undermines planning and elevates refinancing and operational risks.
Read all positive and negative factors
Positive Factors
Negative Factors
Return to revenue growth and net profit
A reversion to revenue growth and a return to positive net income indicate the core care-facilities operations regained traction. Sustained top-line recovery and even modest profits increase capacity to fund operations, rebuild margins and support multi‑period planning.
Read all positive factors
Jiangxi Rimag Group Co., Ltd. Class H (2522) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.61B
Dividend YieldN/A
Average Volume (3M)10.53M
Price to Earnings (P/E)538.0
Beta (1Y)1.05
Revenue Growth14.75%
EPS GrowthN/A
CountryHK
Employees1,342
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.01
Shares Outstanding294,128,080
10 Day Avg. Volume6,254,929
30 Day Avg. Volume10,530,505
Financial Highlights & Ratios
PEG Ratio-6.52
Price to Book (P/B)1.33
Price to Sales (P/S)3.03
P/FCF Ratio45.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.92Price Target Upside34.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.2
Revenue Forecast (FY)HK$1.03B
Jiangxi Rimag Group Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Operating across China, Jiangxi Rimag Group Co., Ltd. specializes in providing medical imaging services. The company delivers a comprehensive suite of diagnostic imaging procedures, including MRI, CT, PET scans, X-rays, ultrasounds, and mammograph...
Jiangxi Rimag Group Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
68
Positive
Cash Flow
52
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 873.12M | 760.59M | 928.91M | 784.44M | 592.01M |
| Gross Profit | 295.24M | 277.33M | 332.60M | 236.95M | 175.19M |
| EBITDA | 223.50M | 169.30M | 256.20M | 207.86M | -147.44M |
| Net Income | 3.75M | -45.92M | 44.41M | 364.00K | -360.73M |
Balance Sheet | |||||
| Total Assets | 2.86B | 2.26B | 1.88B | 1.99B | 2.06B |
| Cash, Cash Equivalents and Short-Term Investments | 626.16M | 262.79M | 215.79M | 355.62M | 509.67M |
| Total Debt | 622.72M | 578.61M | 386.02M | 489.07M | 574.76M |
| Total Liabilities | 853.70M | 779.76M | 543.54M | 673.18M | 752.48M |
| Stockholders Equity | 1.99B | 1.46B | 1.29B | 1.27B | 1.27B |
Cash Flow | |||||
| Free Cash Flow | 57.74M | -298.75M | 104.92M | -73.46M | -124.68M |
| Operating Cash Flow | 177.44M | 12.74M | 201.44M | 198.17M | 18.00M |
| Investing Cash Flow | -334.20M | -327.05M | -117.07M | -251.54M | -151.03M |
| Financing Cash Flow | 524.60M | 383.74M | -235.72M | -96.45M | 452.92M |
Jiangxi Rimag Group Co., Ltd. Class H Technical Analysis
Negative
8.10
Price Trends
7.27
Negative
7.17
Negative
11.14
Negative
Market Momentum
-0.18
Positive
30.92
Neutral
13.59
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2522, the sentiment is Negative. The current price of 8.1 is above the 20-day moving average (MA) of 7.62, above the 50-day MA of 7.27, and below the 200-day MA of 11.14, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 30.92 is Neutral, neither overbought nor oversold. The STOCH value of 13.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2522.
Jiangxi Rimag Group Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$5.09B | 2.65 | 67.29% | ― | 135.34% | ― | |
58 Neutral | HK$31.31B | 43.20 | 6.21% | ― | 37.04% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | HK$2.61B | 537.95 | 0.21% | ― | 14.75% | ― | |
48 Neutral | HK$59.25B | -68.24 | -14.45% | ― | 54.12% | 42.14% | |
46 Neutral | HK$14.88B | -114.18 | -2.97% | ― | 30.48% | 65.41% | |
45 Neutral | HK$1.18B | -2.81 | -18.30% | ― | -31.83% | -19.15% |
* General Sector Average
HK:2522
Jiangxi Rimag Group Co., Ltd. Class H
6.51
-7.97
-55.04%
HK:9663
Sino-Synergy Hydrogen Energy Technology (Jiaxing) Co., Ltd. Class H
3.00
-4.97
-62.36%
HK:0666
Rept Battero Energy Company Ltd Class H
13.40
2.46
22.49%
HK:9880
UBTECH ROBOTICS CORP LTD Class H
117.70
34.65
41.72%
HK:2498
RoboSense Technology Company., Ltd
31.16
-1.89
-5.72%
HK:2598
Lianlian DigiTech Co., Ltd. Class H
4.51
-3.68
-44.93%
Jiangxi Rimag Group Co., Ltd. Class H Corporate Events
Jiangxi Rimag Extends RMB32 Million Loan Facility to Connected Subsidiaries
Jun 2, 2026
Jiangxi Rimag Group Co., Ltd. has agreed to provide up to RMB32 million in cash loans to its connected subsidiaries Rimag Yuntai and Wuhan Ronggongshe under a new financial assistance agreement effective until late 2028. The facility, which sets a...
Jiangxi Rimag to Lift Medical Image Insights Stake to 25.36% via HKD353m Share Deal
Apr 26, 2026
Jiangxi Rimag Group Co., Ltd. has agreed, through a wholly owned subsidiary, to acquire 100% equity interests in two target companies for a combined consideration of about HKD353.4 million, to be paid in consideration shares. Following completion,...
Jiangxi Rimag Outlines Board Line-up and Committee Roles
Apr 23, 2026
Jiangxi Rimag Group Co., Ltd. has announced the current composition of its board of directors, led by chairman and chief executive officer Chen Zhaoyang, alongside two other executive directors, two non-executive directors and three independent no...
Jiangxi Rimag Wins Shareholder Backing on Capital Mandates and Board Changes at 2025 AGM
Apr 23, 2026
Shareholders of Jiangxi Rimag Group Co., Ltd. convened virtually for the 2025 annual general meeting on April 23, 2026, with 35.74% of voting share capital represented. They endorsed the 2025 annual report, the work reports of the board and indepe...
Jiangxi Rimag Group Publishes Audited 2025 Results and Previews Full Annual Report
Mar 31, 2026
Jiangxi Rimag Group Co., Ltd., a Hong Kong-listed joint stock company from mainland China, has a board structure that includes executive, non-executive and independent non-executive directors. The company provides bilingual disclosures and compreh...
Jiangxi Rimag Calls 2025 AGM to Approve Results, Capital Mandates and Board Changes
Mar 31, 2026
Jiangxi Rimag Group Co., Ltd., a Hong Kong–listed PRC joint stock company with a mixed board of executive, non-executive and independent non-executive directors, has announced arrangements for its 2025 annual general meeting to be held onlin...
Jiangxi Rimag Group Names Imaging Expert Meng Tao as Non-Executive Director
Mar 31, 2026
Jiangxi Rimag Group has nominated medical imaging specialist Meng Tao as a non-executive director for its second board term, with his appointment to take effect upon approval at an upcoming general meeting. Meng, a former physician at Fudan Univer...
Jiangxi Rimag Sets March 31 Board Meeting to Approve 2025 Results and Consider Dividend
Mar 19, 2026
Jiangxi Rimag Group Co., Ltd. has scheduled a board meeting for March 31, 2026 to review and approve the consolidated annual results for the year ended December 31, 2025. The board will also consider the publication of these results and decide whe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.